IND regulatory gap-assessment checklist

An IND gap assessment should not begin with a generic checklist. It should begin with the proposed clinical investigation: the product, indication, population, route, dose, duration, starting-dose rationale, monitoring plan, and evidence needed to support that exposure. FDA describes the IND as the mechanism through which a sponsor proceeds with clinical investigation of an investigational drug or biologic, subject to the applicable requirements and review process.

1. Establish the assessment basis

Document the assumptions that define what “ready” means for this specific initial IND:

• Product type, dosage form, route of administration, and manufacturing stage.
• Proposed indication, study population, development phase, and trial design.
• Starting dose, escalation approach, exposure duration, and safety-monitoring strategy.
• FDA center and review division, including any product-specific or modality-specific considerations.
• Relevant prior FDA interactions, written responses, meeting minutes, commitments, and open questions.
• Any information incorporated by reference, held in a master file, or dependent on a third party.

A finding is not meaningful unless it is tied to this basis. The same evidence may be adequate for one proposed exposure and inadequate for another.

2. Administrative and regulatory components

FDA’s administrative-component resources identify core materials that help route, organize, and review an IND. Confirm the applicability, status, ownership, and consistency of items such as:

• Cover letter and clear identification of the initial IND submission.
• Applicable FDA forms, including Forms FDA 1571, 1572, and 3674 where required.
• A detailed table of contents that allows reviewers to locate information efficiently.
• Introductory statement and general investigational plan.
• Investigator’s Brochure, with current product, nonclinical, clinical, and risk information.
• Cross-references, letters of authorization, financial-disclosure materials, and other applicable records.

Check consistency across names, product identifiers, formulation, manufacturer information, study title, protocol number, indication, dose, and version dates. Administrative inconsistency can obscure otherwise adequate scientific content.

3. Chemistry, manufacturing, and controls

Evaluate whether the CMC package is sufficient to characterize the clinical material and support interpretation of the proposed investigation. Review:

• Drug-substance identity, characterization, source, manufacturing process, controls, and specifications.
• Drug-product composition, manufacturing process, in-process controls, release specifications, and analytical methods.
• Method suitability or validation status appropriate to the development phase.
• Impurity, contaminant, adventitious-agent, microbiological, container-closure, and compatibility considerations as applicable.
• Available stability data, protocol, storage conditions, retest or expiry rationale, and clinical-supply coverage.
• Comparability or bridging implications where the clinical material differs from nonclinical or prior human material.

Do not record only whether a document exists. Record whether the data support the actual material, dose, route, duration, and study period proposed.

4. Pharmacology and toxicology

ICH M3(R2) describes general principles for nonclinical studies supporting human clinical trials, while product-specific guidance may add or change expectations. Challenge whether the package addresses:

• Primary and secondary pharmacology relevant to the intended mechanism and potential risk.
• Safety pharmacology, general toxicology, toxicokinetics, and nonclinical pharmacokinetics as applicable.
• Genotoxicity, reproductive toxicity, local tolerance, immunotoxicity, juvenile-animal, abuse-liability, or other studies where relevant.
• Species relevance, study duration, route, exposure margins, recovery, reversibility, and dose-limiting findings.
• Starting-dose and escalation rationale, including how observed toxicities inform clinical monitoring and stopping rules.
• Alignment between the tested material and the proposed clinical material.

5. Clinical protocol and investigator information

The protocol should make the risk-control strategy operational. Assess whether it clearly addresses:

• Objectives, endpoints, design, population, eligibility criteria, dose, route, schedule, and duration.
• Escalation, de-escalation, stopping, pausing, sentinel, and cohort-review rules where applicable.
• Safety assessments, laboratory monitoring, adverse-event collection, and expedited-reporting responsibilities.
• Risk mitigation linked to the nonclinical findings and known or theoretical product risks.
• Statistical rationale appropriate to the study objective and development stage.
• Investigator qualifications, site readiness, pharmacy or product-handling requirements, and informed-consent materials.

6. Previous human experience and integrated consistency

Where prior human exposure exists, confirm that the submission accurately summarizes safety, pharmacokinetics, pharmacodynamics, dose, formulation, and relevant outcomes. Then perform a cross-functional consistency check:

• Do CMC specifications and stability support the material described in the protocol and Investigator’s Brochure?
• Do nonclinical findings drive the clinical eligibility, monitoring, stopping, and escalation rules?
• Does the clinical plan remain within the exposure supported by the nonclinical package?
• Are known uncertainties explicit, and is there an appropriate plan to manage them?
• Are statements consistent across summaries, forms, protocols, reports, and source documents?

7. Convert findings into an executable readiness plan

Every confirmed finding should contain enough information to be managed:

The assessment is complete only when the team can explain what remains unresolved, why it matters, what will close it, and whether the target clinical timeline still rests on credible assumptions.